1. Immunology/Inflammation
    Apoptosis
    Stem Cell/Wnt
  2. SPHK
    Apoptosis
    Wnt
  3. SKI II

SKI II 

Cat. No.: HY-13822 Purity: 99.98%
Handling Instructions

SKI-II is an oral active and synthetic inhibitor of sphingosine kinase (SK) activity, with IC50 values of 78 μM and 45 μM for SK1 and for SK2, respectively. SKI II causes an irreversible inhibition of SK1 by inducing its lysosomal and/or proteasomal degradation.

For research use only. We do not sell to patients.

SKI II Chemical Structure

SKI II Chemical Structure

CAS No. : 312636-16-1

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 79 In-stock
Estimated Time of Arrival: December 31
10 mg USD 72 In-stock
Estimated Time of Arrival: December 31
25 mg USD 144 In-stock
Estimated Time of Arrival: December 31
50 mg USD 252 In-stock
Estimated Time of Arrival: December 31
100 mg USD 468 In-stock
Estimated Time of Arrival: December 31
200 mg USD 840 In-stock
Estimated Time of Arrival: December 31
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

SKI-II is an oral active and synthetic inhibitor of sphingosine kinase (SK) activity, with IC50 values of 78 μM and 45 μM for SK1 and for SK2, respectively. SKI II causes an irreversible inhibition of SK1 by inducing its lysosomal and/or proteasomal degradation[1][2].

IC50 & Target

IC50 value: 78/45 μM (SK1/2)[1][2].

In Vitro

SKI II inhibits cell proliferation by suppressing the Wnt/β-catenin signaling pathway. SKI II promotes the degradation of β-catenin by enhancing Wnt5A[1].
SKI II (1.25 μM, 48 h) in combination with DDP has a clear synergistic effect in human gastric carcinoma SGC7901/DDP cell line[2].

Cell Cytotoxicity Assay[1]

Cell Line: The human gastric carcinoma SGC7901/DDP cell line.
Concentration: 0 μM, 1.25 μM (combined with DDP).
Incubation Time: 48 hours.
Result: SKI II in combination with DDP had a greater effect on the SGC-7901/DDP cells compared with DDP or SKI II alone.
In Vivo

Chronic SKI II (50.0 mg/kg, 3-weekly i.p. for 16 weeks) administration leads to permanent reduction of S1P concentrations in plasma in mice[3].
SKI II (50.0 mg/kg, IP; 100 mg/kg, PO) treatment reduces tumor growth in mice bearing solid tumor model[4].

Animal Model: 8 week-old female LDL-R-/- mice[3].
Dosage: 50.0 mg/kg.
Administration: IP injection daily, 3 days a week for 16 weeks.
Result: A single administration of produced a significant reduction of plasma S1P with the maximum (~40%) observed 12 h after injection. At sacrifice (72 h after last injection) S1P levels were 266 ± 18 ng/mL and 328 ± 30 ng/mL in the SKI-II-treated and control groups, respectively.
Animal Model: BALB/c mouse solid tumor model that uses JC mammary adenocarcinoma cells[4].
Dosage: 50.0 mg/kg.
Administration: IP injection daily, 3 days a week for 16 weeks.
Result: Had strong inhibition of tumor growth from the start of treatment of 65%, with no toxicity or weight loss.
Animal Model: BALB/c JC tumor model[4].
Dosage: 100 mg/kg.
Administration: PO every other day.
Result: Caused significant antitumor activity in well-established tumors as early as day 5, with maximal response seen at the end of the study. Showed 79% inhibition of tumor growth from the start of treatment.
Molecular Weight

302.78

Formula

C₁₅H₁₁ClN₂OS

CAS No.

312636-16-1

SMILES

OC1=CC=C(NC2=NC(C3=CC=C(Cl)C=C3)=CS2)C=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : ≥ 100 mg/mL (330.27 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.3027 mL 16.5136 mL 33.0273 mL
5 mM 0.6605 mL 3.3027 mL 6.6055 mL
10 mM 0.3303 mL 1.6514 mL 3.3027 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.75 mg/mL (9.08 mM); Clear solution

  • 2.

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.75 mg/mL (9.08 mM); Clear solution

*All of the co-solvents are provided by MCE.
References

Purity: 99.98%

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

SKI IISPHKApoptosisWntSphingosine kinaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product name:
SKI II
Cat. No.:
HY-13822
Quantity:
MCE Japan Authorized Agent: